ULBP3 and B-cell chronic lymphocytic leukemia: In independent studies, other NKG2D ligands have emerged as major determinants of tumor cell targeting by γδ T cells: ULBP4 in ovarian and colon carcinomas (46); and ULBP3 in B-cell chronic lymphocytic leukemia (CLL) (47).